Biologic Firm Urges Supreme Court To Reject Prenotice FDA Approval Requirement
WASHINGTON, D.C. — In a March 31 brief, Sandoz Inc. tells the U.S. Supreme Court that rival biologic maker Amgen Inc. and the Federal Circuit U.S. Court of Appeals have improperly...To view the full article, register now.
Already a subscriber? Click here to view full article